All News

California's biotech industry takes its own pulse in a new survey that tracks how the state is doing in serving as the nation's medicine cabinet and avatar of drug innovation.

Shire’s Second Act

Innovation won't happen until the industry is ready to sit down and make a big change.

All eyes are on PatientsLikeMe's new epilepsy site. The social network is backed by UCB, but the pharma firm is taking a hands-off approach. Is this the future of pharma social media?

Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics - Kalido whitepaper

GlaxoSmithKline announced that it would open up its library of prospective molecules and investigational vaccines. This move gives researchers free access to study experimental treatments for illnesses that plague the world's poorest countries.

Pharma Complaint Management : Emerging Challenges and Solutions - Infosys Tech

At time when people can't even get a 3 percent cost-of-living increase, how can pharma justify price hikes pushing 500 percent (in some categories). A new study by the government's General Accountability Office examines why drug products took a massive price leap in recent years.

The push for government transparency continues with Phase I of FDA's plan to expose the inner workings of that secretive cabal known as the Food and Drug Association. First up, fancy new FAQs.

The Big Reset

Thank you

Waters Video Showcase is accessible at waters.com/customers and is the largest such assemblage of expert testimonials in the industry.

December 18, 2009.

December 17, 2009.

Sanofi-Aventis is recalling hundreds of thousands of doses of the childrens' version of its H1N1 vaccine. Conspiracy theorists are going to have a field day.

Transparency can be a double-edged sword - especially if you are a doctor receiving money to speak on behalf of a drug company. Sure the pay day is nice, but does the public outing open you up to scrutiny?

It's been a tough week for clinical trials: One drug got canned and another was re-tuned in the wake of failed end points and patient deaths.

December 15, 2009.

PharmRep Editorial Calendar

11 December.

Painkiller abuse has become so prevalent that FDA is working with pharma to create a strategy for handling misuse of all drugs across the entire opioid category.

Drug manufacturers came under fire at a hearing of the House Energy and Commerce?s health subcommittee for bumping drug prices 10 percent this year. Pharma claims rumors that it?s boosting costs in anticipation of healthcare reform are baseless, but the industry could be facing an uphill battle.

Reid Paul, Editor-in-Chief of Pharmaceutical Representative Magazine joins host George Koroneos to discuss the top five pharmaceutical industry news stories of the week

With the fourth quarter quickly coming to a close, talks of job cuts are once again in the air. The first major layoffs could be coming at Sanofi-Aventis, which is rumored to be slashing up to 1,500 positions.

A new study of industry tax professionals conducted by PricewaterhouseCoopers predicts higher taxes for Big Pharma in the wake of the global economic downturn. What can your company do to remain competitive and discover new incentives?

As the old orthodoxy shatters, pharma must stand firm or leave the field.

Our sixth annual pipeline report details 44 drugs that industry will be talking about in 2010.

The fight against cancer may be the litmus test for how regulation and private investment work together to address the disease burden.